Akebia Therapeutics Inc. (AKBA) Plunges 15.42%

Akebia Therapeutics Inc. (AKBA) Plunges 15.42%

Akebia Therapeutics Inc. (AKBA) had a rough trading day for Monday December 02 as shares tumbled 15.42%, or a loss of $-0.97 per share, to close at $5.32. After opening the day at $6.19, shares of Akebia Therapeutics Inc. traded as high as $6.28 and as low as $5.26. Volume was 3.48 million shares over 18,512 trades, against an average daily volume of n/a shares and a total float of 118.86 million.

As a result of the decline, Akebia Therapeutics Inc. now has a market cap of $632.36 million. In the last year, shares of Akebia Therapeutics Inc. have traded between a range of $10.45 and $2.99, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.

Akebia Therapeutics Inc. is based out of Cambridge, MA and has some 325 employees. Its CEO is John P. Butler.

Akebia Therapeutics Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

error: Content is protected !!